Top U.S. Stock Gainers After the Bell on December 10, 2025: ASPC, BBGI, ENVB, PLAB, IRBT, AHT Lead Fed‑Day Rally

New York – December 10, 2025 — Wall Street closed higher on Wednesday after the Federal Reserve delivered its third interest‑rate cut of 2025, lifting the Dow, S&P 500 and Nasdaq and setting the stage for a powerful “stock picker’s” session beneath the surface. ^[1]

While the major indices moved less than 1% each, a cluster of small‑ and mid‑cap names exploded higher by 40–390% during regular trading, with several of them still among the biggest movers in after‑hours trading. According to StockAnalysis, the top 10 U.S. gainers by percentage at the close were dominated by micro‑caps, speculative biotech, and one fundamentally strong semiconductor supplier. ^[2]

Below is a breakdown of the day’s top gainers, the news behind each move, and what traders and investors are watching next.

Market backdrop: Fed cuts again, indices grind higher

The Federal Reserve cut its benchmark rate by 25 basis points to a range of 3.50%–3.75%, its third cut of 2025, and signaled a likely pause while it waits for clearer data on inflation and the labor market. ^[3]

Major U.S. indices reacted positively:

• Dow Jones Industrial Average: +1.05% to 48,061.32
• S&P 500: +0.67% to 6,886.26
• Nasdaq Composite: +0.33% to 23,654.40 ^[4]

Commentary from Fed Chair Jerome Powell stressed that another rate hike is “not anybody’s base case,” which investors read as a green light for risk assets, helping push the S&P 500 toward a fresh closing record. ^[5]

Against this backdrop, liquidity flowed into high‑beta pockets of the market, fueling outsized moves in thinly traded names — and one earnings‑fueled semiconductor winner.

Top U.S. stock gainers after the bell – December 10, 2025

Based on closing‑bell data from StockAnalysis, these were the top 10 percentage gainers on U.S. exchanges today: ^[6]

1. Beasley Broadcast Group (NASDAQ: BBGI) – +389.63% to $19.83
2. HeartBeam (NASDAQ: BEAT) – +107.95% to $1.68
3. A SPAC III Acquisition Corp. (NASDAQ: ASPC) – +90.84% to $20.00
4. Biodexa Pharmaceuticals (NASDAQ: BDRX) – +72.24% to $7.01
5. Enveric Biosciences (NASDAQ: ENVB) – +67.40% to $9.91
6. Creative Global Technology Holdings (NASDAQ: CGTL) – +51.39% to $0.999
7. TaoWeave (NASDAQ: TWAV) – +45.45% to $2.40
8. iRobot (NASDAQ: IRBT) – +44.19% to $5.09
9. Photronics (NASDAQ: PLAB) – +44.02% to $37.00
10. Ashford Hospitality Trust (NYSE: AHT) – +42.09% to $4.49

In after‑hours trading, ASPC, ENVB and AHT stayed among the strongest names, with ASPC and ENVB topping StockAnalysis’ after‑hours winners list as moves extended beyond the close. ^[7]

Let’s break down what drove these outsized moves — and what forecasts and commentary are emerging from today’s news flow.

Beasley Broadcast Group (BBGI): nearly +390% on low float and speculation

Move: +389.63% to $19.83, topping today’s gainer list. ^[8]

Radio and digital‑media operator Beasley Broadcast Group staged a stunning multi‑hundred‑percent rally on huge volume (over 42 million shares versus a micro‑cap market cap of ~$36 million). ^[9]

Key details from today’s coverage:

• Benzinga flagged BBGI as the standout name in a list of communication services movers, citing a 343% intraday surge and unusually high volume. ^[10]
• RTTNews reported the stock “skyrocketed over 245%” earlier in the session before extending gains, with no major earnings or M&A announcement to justify the magnitude of the move. ^[11]
• Stockstotrade asked bluntly whether Beasley’s spike is sustainable, highlighting BBGI’s low float, distressed long‑term chart, and heavy day‑trader interest as classic ingredients for a short‑term squeeze rather than a fundamental re‑rating. ^[12]

Fundamentally, the only fresh corporate headline today was a Beasley executive joining the board of the Media Institute — hardly the kind of event that normally fuels a 4x move. ^[13]

Takeaway & outlook:
Most coverage characterizes BBGI’s rally as speculative and technically driven, with little in the way of new earnings or strategic news. That means forecasts are less about discounted cash flows and more about trader behavior:

• Short‑term screens and social chatter may keep BBGI on momentum traders’ watchlists.
• Without a follow‑up catalyst (asset sale, refinancing, or digital pivot), analysts and trading newsletters warn that a sharp retracement is a real risk once liquidity and attention fade. ^[14]

HeartBeam (BEAT): FDA win and a big price‑target hike

Move: +107.95% to $1.68. ^[15]

Cardiac‑diagnostics company HeartBeam was the second‑biggest gainer after securing a pivotal regulatory milestone and an aggressive analyst upgrade:

• The company announced FDA 510(k) clearance for the first cable‑free, synthesized 12‑lead ECG solution designed for at‑home arrhythmia assessment, a device that can capture ECG signals in 3D and generate a full 12‑lead readout remotely. ^[16]
• Benzinga highlighted the stock’s surge, noting explosive volume — far above average — as traders piled into the micro‑cap on the news. ^[17]
• HC Wainwright reiterated a “Buy” rating and more than doubled its price target from $2.50 to $5.50, implying substantial upside even after today’s move. ^[18]
• Stockstotrade described BEAT’s rally as a “leap” driven by a mix of real news (FDA clearance) and speculative momentum, while warning about the name’s extreme volatility and thin float. ^[19]

Takeaway & outlook:
Unlike many of today’s winners, HeartBeam’s move is anchored in clear fundamental news. The FDA clearance opens the door to commercialization in remote arrhythmia monitoring, a market that dovetails with telehealth and home‑diagnostics trends.

Short‑term, traders are watching whether:

• BEAT can hold above key technical levels identified in intraday analyses. ^[20]
• Additional payor, partnership or launch updates follow in coming quarters to support the new, higher analyst target.

A SPAC III Acquisition (ASPC): blank‑check mania and after‑hours momentum

Move: +90.84% to $20.00 at the close; among the biggest after‑hours gainers as well. ^[21]

A SPAC III Acquisition Corp., a Hong Kong–based blank‑check company still searching for a merger target, became one of the day’s most volatile tickers:

• Pre‑market, ASPC was already on “top gainers” and “morning market movers” lists as traders rotated into low‑float SPACs ahead of the Fed decision. RTTNews highlighted it among early high‑volatility names. ^[22]
• Real‑time quote services showed ASPC swinging wildly, with intraday highs far above prior days’ $10–$11 range before settling near $20. ^[23]
• Benzinga’s ASPC quote page and SPACResearch profile both underscore the absence of an announced deal and the stock’s status as a shell focused on future business combinations. ^[24]

There was no merger announcement, PIPE deal, or new fundamental filing today; the jump appears driven by a familiar formula: low float + options activity + copycat trades chasing recent SPAC runners. ^[25]

Takeaway & outlook:
With no published Wall Street earnings or formal price‑target consensus, today’s commentary focuses on risk rather than valuation. Analysts and SPAC trackers note:

• Any future definitive merger agreement could re‑anchor ASPC’s price to the fundamentals of a target business.
• In the meantime, the stock’s behavior fits the pattern of short‑term trading vehicles that can move 50–100% in a day — up or down — on sentiment alone.

Biodexa Pharmaceuticals (BDRX): violent biotech rally with “toxic financing” overhang

Move: +72.24% to $7.01. ^[26]

UK‑based Biodexa Pharmaceuticals is developing therapies for familial adenomatous polyposis (FAP) and type 1 diabetes, but today’s rally is as much about structure as science:

• Stockstotrade and other trading outlets flagged BDRX as a major mover, with intraday gains of 30–70% as it repeatedly appeared on “pre‑market movers” and “top gainers” lists in early December. ^[27]
• A detailed TechStock² feature describes BDRX’s Phase 3 FAP program and a highly complex Form F‑1 financing, which includes zero‑cash warrants and a multi‑layered unit structure. Commentators warn this could create what critics call “death‑spiral” dilution under certain conditions. TechStock²
• That same analysis notes algorithmic and quant services are split: some label BDRX a “strong sell” based on volatility and trend, while one forecasting model sees potential for significant upside over 12 months — underscoring how binary and speculative the story is. TechStock²
• Tim Sykes’ trading site also highlighted the stock’s violent swings, framing today’s move as part of a momentum‑driven loop where halts, thin float and social buzz amplify each push higher or lower. ^[28]

Takeaway & outlook:
Fundamentally, BDRX offers exposure to late‑stage rare‑disease drug development — but the capital structure is extremely high‑risk. Analysts and model‑driven services cited today stress:

• Ongoing dilution risk from warrants and shelf registrations. TechStock²
• The possibility that short squeezes and halts overshadow incremental clinical news for long stretches of time.

For long‑term investors, coverage generally frames BDRX as a binary bet where position sizing and risk tolerance matter more than headline price targets.

Enveric Biosciences (ENVB): patent momentum and after‑hours strength

Move: +67.40% to $9.91; also one of the top after‑hours gainers. ^[29]

Enveric Biosciences, a neuroplastogenic‑drug developer, rallied on both IP news and speculative appetite:

• The company announced a Notice of Allowance from the U.S. Patent and Trademark Office covering parts of its EVM301 series, a family of next‑generation molecules aimed at neuropsychiatric and addiction disorders. ^[30]
• Management emphasized that the notice expands Enveric’s patent estate around its lead candidate EB‑003, designed to target 5‑HT₂A and 5‑HT₁B receptors to deliver fast‑acting antidepressant effects without hallucinogenic side effects. ^[31]
• Trading‑focused outlets framed ENVB as “poised for growth,” pointing to triple‑digit percentage moves and heightened investor optimism after the patent news and prior FDA‑related designations. ^[32]
• A Schedule 13G/A filing discussed in today’s coverage showed one fund exiting its beneficial ownership, underscoring how rapid shifts in the shareholder base can interact with the stock’s thin float. ^[33]

Takeaway & outlook:
Analysts and newsletters agree that Enveric remains an early‑stage, high‑volatility biotech, but note that:

• The strengthening IP moat around EVM301 and EB‑003 could support future partnership or funding talks. ^[34]
• At the same time, forecast models and commentary stress that the path from preclinical or early‑clinical neuropsychiatric assets to revenue is long, and today’s price action may not track fundamentals closely in the near term. ^[35]

Photronics (PLAB): earnings‑powered breakout in semiconductor photomasks

Move: +44.02% to $37.00, making Photronics the day’s standout mid‑cap winner. ^[36]

Unlike many micro‑cap flyers on today’s list, Photronics’ move is firmly grounded in earnings and guidance:

• The photomask manufacturer reported Q4 2025 revenue of $215.8 million, beating analyst estimates of about $205 million, with non‑GAAP EPS of $0.60 vs. roughly $0.45 expected. ^[37]
• An Investing.com breakdown noted that high‑end integrated circuit (IC) revenue grew strongly and that margins improved, driving robust operating cash flow. ^[38]
• Management guided Q1 FY 2026 revenue to $217–$225 million with an operating margin of 23–25%, reinforcing a bullish multi‑quarter outlook tied to AI, data‑center demand and semiconductor regionalization trends. ^[39]

Commentary today highlights several bullish themes:

• Photronics is positioned as a key enabler of advanced IC and display manufacturing, benefiting as photomasks grow more complex (and more valuable) at smaller technology nodes. ^[40]
• The company’s strong balance sheet — high cash, negligible debt — gives it flexibility to fund capacity expansions in the U.S. and Asia amid government‑backed chip‑fabrication build‑outs. ^[41]

Takeaway & outlook:
Among today’s top gainers, PLAB is one of the few where fundamental analysts are broadly supportive of the move. Coverage frames the stock as:

• A levered play on secular semiconductor growth and fab reshoring.
• Still sensitive to cyclical swings, but backed by concrete earnings beats and guidance rather than purely speculative flows.

iRobot (IRBT): meme‑style short squeeze returns to the Roomba maker

Move: +44.19% to $5.09. ^[42]

Home‑robotics pioneer iRobot once again found itself in meme‑stock territory:

• Business Insider reported that shares were up roughly 72% in four days on little company‑specific news, with retail traders openly framing it as a new short‑squeeze candidate. Short interest sits around 40% of float, and days‑to‑cover has collapsed to roughly 0.14, indicating intense trading volume. ^[43]
• MarketMinute’s analysis described today’s move as a retail‑driven squeeze that “defies fundamental headwinds,” pointing to declining revenue, ongoing losses and a strategic review that is still unresolved. ^[44]
• Vacuum‑focused outlet Vacuum Wars also highlighted recent spikes, tying speculative interest partly to U.S. policy talk around domestic robotics investment, which retail investors have latched onto as a narrative tailwind. ^[45]

Takeaway & outlook:
Today’s commentary is nearly unanimous:

• Short‑term, IRBT’s price action will likely be dictated by the tug‑of‑war between short sellers and retail traders, not by incremental fundamental news. ^[46]
• Longer‑term forecasts remain cautious: analysts stress that iRobot still needs a credible plan to stabilize sales, shore up its balance sheet and resolve its strategic review for any squeeze‑driven gains to prove durable. ^[47]

Ashford Hospitality Trust (AHT): strategic alternatives trigger a re‑rating

Move: +42.09% to $4.49; also strong in after‑hours trading. ^[48]

Hotel REIT Ashford Hospitality Trust rallied after the company announced it is formally considering strategic alternatives:

• A PRNewswire release yesterday revealed that AHT’s board formed a special committee to evaluate options “including a potential transaction” aimed at maximizing shareholder value. ^[49]
• An Investing.com recap emphasized that the REIT simultaneously terminated non‑traded preferred offerings and suspended redemptions, while noting the stark disconnect between Ashford’s $200+ million in EBITDA and its roughly $20–30 million market capitalization following a 65% share‑price decline over the past year. ^[50]

Takeaway & outlook:
The market is now betting on some combination of:

• Asset sales, balance‑sheet cleanup or a take‑private / sale scenario that narrows the gap between asset value and equity price. ^[51]
• However, coverage also highlights risks: hospitality remains sensitive to economic slowdown and financing costs, and prior restructurings in the sector show that strategic reviews do not always end in premium buyouts.

Other notable high‑beta winners: CGTL, TWAV, MIGI, SIDU

Beyond the headline names, several smaller stocks also exploded higher:

• Creative Global Technology Holdings (CGTL) – +51.39%
  • The Hong Kong‑based electronics recycler has recently battled Nasdaq minimum bid‑price issues and posted mixed profitability. ^[52]
  • Forecast services like CoinCodex actually project a short‑term pullback, underscoring the disconnect between today’s momentum and algorithmic outlooks. ^[53]
• TaoWeave (TWAV) – +45.45%
  • Formerly known as Oblong, the company rebranded to TaoWeave and began trading today under ticker TWAV as a digital‑asset treasury company focused on TAO holdings, launching a real‑time on‑chain treasury dashboard for investors. ^[54]
• Mawson Infrastructure Group (MIGI) – +40.22%
  • The Bitcoin‑mining and digital‑infrastructure provider has drawn attention from blockchain stock watchlists and conference organizers, with an Emerging Growth Conference keynote scheduled for December 11 following a recent reverse split. ^[55]
• Sidus Space (SIDU) – +39.46%
  • The space‑technology company announced successful bus‑level commissioning of its LizzieSat‑3 satellite, including autonomous navigation capabilities, which helped send shares sharply higher. ^[56]

These names share a common thread: micro‑cap status, sector buzz (blockchain, space, AI) and news that, while meaningful, may not fully justify the size of one‑day moves without the amplifying effect of speculative flows.

What today’s biggest gainers signal about this market

Today’s leaderboard tells a clear story about where risk appetite is strongest on Fed‑cut days:

• Speculative micro‑caps dominate: BBGI, ASPC, BDRX, ENVB, CGTL, TWAV, MIGI and SIDU are all thinly traded, news‑sensitive names that can move dozens or hundreds of percent in a single session. ^[57]
• Short‑squeeze setups are back: IRBT’s rally, and the chatter around high short interest and minimal days‑to‑cover, show that meme‑style trades remain very much alive in 2025. ^[58]
• Fundamentals still matter for select winners: Photronics stands out as a case where earnings beats, robust guidance and structural industry tailwinds line up with the share‑price move. ^[59]

For traders, the key questions are whether these moves attract follow‑through volume in coming days — or whether they fade as quickly as they appeared. For longer‑term investors, today’s action is a reminder that:

• Extraordinary one‑day gains often come with equally extraordinary downside risk, particularly in low‑float and heavily diluted names. TechStock²+1
• Even when the macro backdrop (like a Fed rate cut without hawkish guidance) is supportive, position sizing and diversification remain critical.

Important note: This article is for information and news purposes only and does not constitute financial advice, stock recommendations or an offer to buy or sell any security. Always do your own research or consult a licensed financial adviser before making investment decisions.

References

1. www.reuters.com, 2. stockanalysis.com, 3. www.reuters.com, 4. www.reuters.com, 5. www.investopedia.com, 6. stockanalysis.com, 7. stockanalysis.com, 8. stockanalysis.com, 9. stockanalysis.com, 10. www.benzinga.com, 11. www.rttnews.com, 12. stockstotrade.com, 13. www.marketscreener.com, 14. stockstotrade.com, 15. stockanalysis.com, 16. ir.heartbeam.com, 17. www.benzinga.com, 18. www.gurufocus.com, 19. stockstotrade.com, 20. stockstotrade.com, 21. stockanalysis.com, 22. www.rttnews.com, 23. stockanalysis.com, 24. www.spacresearch.com, 25. www.investing.com, 26. stockanalysis.com, 27. stockstotrade.com, 28. www.timothysykes.com, 29. stockanalysis.com, 30. www.biospace.com, 31. www.biospace.com, 32. stockstotrade.com, 33. www.streetinsider.com, 34. www.biospace.com, 35. www.timothysykes.com, 36. stockanalysis.com, 37. www.investing.com, 38. www.investing.com, 39. www.investing.com, 40. www.investing.com, 41. www.investing.com, 42. stockanalysis.com, 43. www.businessinsider.com, 44. markets.financialcontent.com, 45. vacuumwars.com, 46. markets.financialcontent.com, 47. markets.financialcontent.com, 48. stockanalysis.com, 49. www.prnewswire.com, 50. www.investing.com, 51. www.investing.com, 52. stockanalysis.com, 53. coincodex.com, 54. www.businesswire.com, 55. stockanalysis.com, 56. finance.yahoo.com, 57. stockanalysis.com, 58. www.businessinsider.com, 59. www.investing.com